Insmed Target of Unusually Large Options Trading (INSM)

Insmed Incorporated (NASDAQ:INSM) saw unusually large options trading on Monday. Stock investors bought 896 put options on the stock. This is an increase of approximately 679% compared to the typical volume of 115 put options.

INSM has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Insmed in a report on Monday, November 6th. Cowen reaffirmed a “buy” rating and issued a $54.00 price objective on shares of Insmed in a research note on Friday, November 3rd. BidaskClub raised Insmed from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Zacks Investment Research lowered Insmed from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Finally, ValuEngine raised Insmed from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. Insmed presently has an average rating of “Buy” and a consensus price target of $34.50.

Shares of Insmed (NASDAQ INSM) opened at $32.99 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 15.21 and a quick ratio of 15.21. The company has a market capitalization of $2,530.00, a PE ratio of -10.57 and a beta of 1.18. Insmed has a 52-week low of $11.49 and a 52-week high of $33.54.

In related news, Director Donald J. Hayden, Jr. sold 15,000 shares of Insmed stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $32.50, for a total value of $487,500.00. Following the completion of the sale, the director now owns 71,131 shares of the company’s stock, valued at $2,311,757.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company lifted its position in shares of Insmed by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 49,163 shares of the biopharmaceutical company’s stock worth $844,000 after buying an additional 197 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Insmed by 2.0% in the second quarter. Legal & General Group Plc now owns 20,173 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 390 shares in the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Insmed by 11.2% in the second quarter. Parametric Portfolio Associates LLC now owns 16,035 shares of the biopharmaceutical company’s stock worth $275,000 after buying an additional 1,618 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Insmed by 0.9% in the second quarter. TIAA CREF Investment Management LLC now owns 213,525 shares of the biopharmaceutical company’s stock worth $3,664,000 after buying an additional 1,857 shares in the last quarter. Finally, Voya Investment Management LLC lifted its position in shares of Insmed by 9.3% in the second quarter. Voya Investment Management LLC now owns 27,960 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 2,389 shares in the last quarter. Institutional investors own 95.28% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/04/insmed-target-of-unusually-large-options-trading-insm-2.html.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply